Non-viral vector as vaccine carrier.
Over the last several years, advances in gene-based delivery technology arising from the field of gene therapy have helped revitalize the field of vaccine development. Genetic vaccination encoding antigen from bacteria, virus, and cancer has shown promise in protective humoral and cellular immunity; however, the potential disadvantages of naked DNA vaccine have reduced the value of the approach. To optimize antigen delivery efficiency as well as vaccine efficacy, the non-viral vector as vaccine carrier, for example, the cationic liposome, has shown particular benefits to circumvent the obstacles that both peptide/protein- and gene-based vaccines have encountered. Liposome-mediated vaccine delivery provides greater efficacy and safer vaccine formulation for the development of vaccine for human use. The success of the liposome-based vaccine has been demonstrated in clinical trials and further human trials are also in progress.
Chen
Weihsu Claire
WC
Center for Pharmacogenetics, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA.
Huang
Leaf
L
D000818:Animals; D000917:Antibody Formation; D000938:Antigen-Presenting Cells / Q000276:immunology; D019496:Cancer Vaccines / Q000008:administration & dosage; D004337:Drug Carriers; D005822:Genetic Vectors; D006801:Humans; D007111:Immunity, Cellular; D007155:Immunologic Factors / Q000008:administration & dosage; D008081:Liposomes; D017780:Malaria Vaccines / Q000008:administration & dosage; D008297:Male; D051379:Mice; D009369:Neoplasms / Q000628:therapy; D011471:Prostatic Neoplasms / Q000628:therapy; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D019444:Vaccines, DNA / Q000008:administration & dosage* / Q000235:genetics; D022223:Vaccines, Subunit / Q000008:administration & dosage
D019496:Cancer Vaccines; D004337:Drug Carriers; D007155:Immunologic Factors; D008081:Liposomes; D017780:Malaria Vaccines; D019444:Vaccines, DNA; D022223:Vaccines, Subunit